ProBioGen has signed a commercial multi-product license agreement with Sanofi. Under the agreement, Sanofi will integrate ProBioGen’s GlymaxX technology into its product development strategy for an undisclosed number of antibody candidates across several business units.
ProBioGen says GlymaxX enables a boost of antibody-dependent cell-mediated cytotoxicity (ADCC), consequently leading to an elevated NK cell mediated killing activity of its target cells. The technology is claimed to significantly improving medicine potency and potentially reduce the overall clinical doses for patients.
The GlymaxX technology for production of afucosylated proteins is used in various mAb candidates. The technology reportedly allows a modified cell line to produce both, completely fucosylated and/or afucosylated antibodies and those with intermediate defined fuscosylation levels.
The technology can be integrated in development, or in pre-existing cell lines of different host cell origins.
